Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01712542
Other study ID # JohannWGUH_Curcumin-01
Secondary ID
Status Completed
Phase Phase 0
First received October 20, 2012
Last updated June 1, 2013
Start date October 2012
Est. completion date May 2013

Study information

Verified date June 2013
Source Johann Wolfgang Goethe University Hospitals
Contact n/a
Is FDA regulated No
Health authority Regierungspräsidium Darmstadt: Germany
Study type Observational

Clinical Trial Summary

Measuring the bioavailability of orally administered curcumin in the tumors of glioblastoma patients.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date May 2013
Est. primary completion date May 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients harboring Glioblastoma

- Patient will undergo surgery

Exclusion Criteria:

- BMI > 30

- Liver and Kidney Function so compromised that medication is prescribed

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms

  • Glioblastoma
  • Patient Harboring Glioblastoma That Will Undergo Surgery

Locations

Country Name City State
Germany Department of Neurosurgery, Johann Wolfgang Goethe-University Frankfurt Hessen

Sponsors (1)

Lead Sponsor Collaborator
Johann Wolfgang Goethe University Hospitals

Country where clinical trial is conducted

Germany, 

References & Publications (1)

Senft C, Polacin M, Priester M, Seifert V, Kögel D, Weissenberger J. The nontoxic natural compound Curcumin exerts anti-proliferative, anti-migratory, and anti-invasive properties against malignant gliomas. BMC Cancer. 2010 Sep 14;10:491. doi: 10.1186/1471-2407-10-491. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Concentration of Curcumin in Glioblastoma At the time of surgery At Tumor resection No

External Links